ストックスクリーナーアプリを入手
28.93
2.08%
0.59
アフターアワーズ：
28.93
Beam Therapeutics Inc (BEAM) 最新ニュース
Is Beam Therapeutics Inc. stock a defensive play in 2025Resistance Zone Identification & Free High Profit Capital Plays - ulpravda.ru
UBS Initiates Coverage on Beam Therapeutics (BEAM) with Neutral - GuruFocus
Beam Therapeutics stock initiated with Neutral rating by UBS - Investing.com UK
How Investors Are Reacting To Beam Therapeutics (BEAM) ARK’s Renewed Bet On Base-Editing Biotech - Yahoo Finance
Beam Therapeutics stock rises 5% after BofA lifts target to $45 - TechStock²
Beam Therapeutics (NASDAQ:BEAM) Shares Up 11.1%What's Next? - MarketBeat
Will Beam Therapeutics Inc. stock benefit from infrastructure spendingStock Price Forecasts & Low Cost Wealth Building - bollywoodhelpline.com
BofA Adjusts Price Target on Beam Therapeutics to $45 From $43, Maintains Buy Rating - MarketScreener
Beam Therapeutics soars 64% after InvestingPro’s undervalued call in April By Investing.com - Investing.com
ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure - Yahoo Finance
ARK Invest Boosts Stake in Beam Therapeutics (BEAM) Amid Biotech Focus - GuruFocus
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Rating Increased to Hold at Wall Street Zen - MarketBeat
Beam Therapeutics stock initiated with Neutral rating by UBS By Investing.com - Investing.com Nigeria
Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? - The Globe and Mail
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks - Benzinga
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab - TradingView — Track All Markets
Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene - Finviz
Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock? - Yahoo Finance
(BEAM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
12 Best Genomics Stocks to Invest In - Insider Monkey
Death Cross: Is Beam Therapeutics Inc. stock a defensive play in 2025Exit Point & Safe Entry Zone Identification - moha.gov.vn
Beam Therapeutics Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy - Finviz
Prime Editing & CRISPR Market Set to Revolutionize Gene Therapy: - openPR.com
Growth Value: Will Beam Therapeutics Inc. stock benefit from infrastructure spending2025 Price Action Summary & Short-Term High Return Strategies - Улправда
Is Beam Therapeutics Inc. stock a safe investment in uncertain marketsWeekly Trading Summary & Daily Price Action Insights - Улправда
Targets Report: What margin trends mean for Beam Therapeutics Inc. stockPortfolio Performance Report & Expert Approved Trade Ideas - Улправда
Growth Report: Is Beam Therapeutics Inc. stock attractive for retirement portfoliosJuly 2025 Technicals & Reliable Entry Point Alerts - Улправда
Will Beam Therapeutics Inc. stock reach all time highs in 20252025 Buyback Activity & Low Risk High Win Rate Picks - DonanımHaber
Will Beam Therapeutics Inc. stock beat EPS estimatesCEO Change & Capital Protection Trading Alerts - DonanımHaber
Is Beam Therapeutics Inc. stock cheap compared to fundamentalsMarket Growth Report & Short-Term High Return Strategies - Улправда
Price-Driven Insight from (BEAM) for Rule-Based Strategy - Stock Traders Daily
Aug Final Week: Is Beam Therapeutics Inc. stock a defensive play in 2025July 2025 EndofMonth & Free Community Consensus Stock Picks - ulpravda.ru
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
What margin trends mean for Beam Therapeutics Inc. stockEarnings Risk Summary & Reliable Volume Spike Alerts - ulpravda.ru
Beam Therapeutics Inc. $BEAM Shares Acquired by Squarepoint Ops LLC - MarketBeat
Is Beam Therapeutics Inc. stock attractive for retirement portfoliosJuly 2025 EndofMonth & Reliable Price Breakout Signals - Улправда
How resilient is Beam Therapeutics Inc. stock in market downturnsJuly 2025 Price Swings & Daily Growth Stock Investment Tips - Улправда
Technical Analysis: Why Beam Therapeutics Inc stock is trending among retail tradersTrade Signal Summary & Weekly Momentum Picks - moha.gov.vn
Nikko Asset Management Americas Inc. Increases Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Bellevue Group AG Raises Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Advances BEAM-302 Study for AATD: Key Insights for Investors - MSN
Cambridge biotech receives $255M in sale of spinout to BMS - The Business Journals
Beam Therapeutics Inc. $BEAM Holdings Lowered by Redmile Group LLC - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Evercore ISI Remains a Buy on Beam Therapeutics (BEAM) - The Globe and Mail
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions - PR Newswire
Beam Therapeutics (BEAM) Receives a Buy from Bank of America Securities - The Globe and Mail
JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
ASH: Beam Can Rival Vertex In Sickle Cell But Bulsufan Deaths Cast A Shadow - Citeline News & Insights
Beam Therapeutics edges higher after new sickle cell therapy results - MSN
Beam Therapeutics stock rises on promising sickle cell therapy data By Investing.com - Investing.com Nigeria
28.63%
大文字化:
|
ボリューム (24 時間):